Nature Biotechnology 2017-07-12

Public biotech in 2016—the numbers

Chris Morrison, Riku Lähteenmäki

Index: 10.1038/nbt.3917

Full Text: HTML

Abstract

The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

Latest Articles:

A wellness study of 108 individuals using personal, dense, dynamic data clouds

2017-07-17

[10.1038/nbt.3870]

Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy

2017-07-17

[10.1038/nbt.3892]

Wanted: biotech for an aging population

2017-07-12

[10.1038/nbt.3925]

An emerging model for life sciences commercialization

2017-07-12

[10.1038/nbt.3911]

CRISPR–Cas9 claim sets and the potential to stifle innovation

2017-07-12

[10.1038/nbt.3913]

More Articles...